IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2].

IMMH001 is converted to the active form, its monophosphate ester (S)-IMMH001-P, by sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2) in vivo [1]. IMMH001 suppresses both Th1 cell (IL-1β, IL-18, and IP10) and Th2 cell (IL-5)-mediated disease reactions in damaged joints [2]. IMMH001 (0.3-2.4 mg/kg, Orally; twice a week, for 28 days, AA rats; for 30 days, CIA rats) relieves the damage of AA (adjuvant-induced arthritis) and CIA (collagen-induced arthritis) rats’ joints [2].